2011 年 12 月 1 日，加利福利亚州圣克拉拉市 – 安捷伦科技公司（纽约证交所：A）前宣布了通过两项战略性收购扩张其生命科学业务。其中一项是收购 Halo Genomics 公司，该公司专注于为快速增长的新一代 DNA 测序市场提供创新技术。此外，安捷伦还与 BioSystem Development 公司签署了最终收购协议，该公司专为生命科学行业的分析需求开发和提供解决方案。
 
    这两家公司均为私人所有。具体财务细节尚未披露。
 
    安捷伦生命科学事业部总裁 Nick Roelofs 说道：“生命科学是安捷伦公司增长的强劲引擎，从战略上讲这两项收购十分关键。我们由此获得了这两个重要领域的全球一流的技术和专家团队，从而使我们能够扩展产品线，为客户提供最全面的工作流程解决方案。”
 
    安捷伦对位于瑞典乌普萨拉科学园的 Halo 公司的收购已落下帷幕。而对总部位于美国威斯康星州麦迪逊的 BioSystem Development 的资产收购按照通常的成交流程，有望在今年底完成。
 
Halo Genomics 简化重测序流程
 
    Halo Genomics 的技术解决了新一代测序中的序列选择性（也称“靶向序列捕获”）样品制备难题。公司的HaloPlex专利技术将基于聚合酶链反应的序列捕获系统的速度和特异性以及基于液相杂交体系的可扩展性和捕获片段大小的灵活性完美融合，从而不再需要进行文库构建。这种用于新一代测序的快捷的靶向序列捕获解决方案有利于解决与靶向重测序相关的瓶颈问题，无需再使用昂贵的专用仪器和繁琐的实验方法。
 
    Halo Genomics 目前的 HaloPlex 技术是以定制产品的方式提供，通过使用在线设计工具“在线设计向导（Web Design Wizard）”定制而成。借助这款高度直观的工具，用户能够在十分钟以内完成设计，而且无需任何费用。
 
    安捷伦全球领先的SureSelect 靶向序列捕获平台是业内首款商业化溶液型靶向序列捕获产品。目前已经壮大成为庞大的产品系列，从全外显子试剂盒到定制片段试剂盒再到预定义产品，丰富多样。SureSelect 凭借其超高性能和出色的灵活性，当之无愧地成为业内引用率最高的靶向序列捕获工具。HaloPlex 技术为 SureSelect 带来捕获小片段样品的高性能解决方案，捕获速度能够满足台式测序仪和临床测序领域的需求。
 
    安捷伦生命科学事业部生物学系统分部副总裁兼总经理 Gustavo Salem 表示：“Halo Genomics一流的技术和顶尖的研发团队使安捷伦如虎添翼，我们将大力开发针对新兴测序应用的解决方案，并加速进军高速发展的新一代临床测序领域。这次收购将进一步奠定安捷伦作为基因组学行业领跑者的地位。”
 
    Halo Genomics 前 CEO 和创始人 Olle Ericsson 谈到：“不管是 Halo 的员工还是我们尊贵的客户，对于 Halo 加入安捷伦都是乐见其成的。Halo 的创新技术加上安捷伦一流的产品和长久以来的质量和服务保证，我们期待为客户带来更多的解决方案套装，全面满足各种需求。”
 
有关 Halo Genomics 技术和服务的更多信息，请访问 www.halogenomics.com。

BioSystem Development 满足药物开发领域不断发展的样品制备需求
 
    BioSystem Development 目前为安捷伦自动化解决方案业务提供 AssayMAP 色谱柱，该色谱柱与安捷伦 Bravo 液体处理平台结合用于蛋白质纯化和活性分析工作流程。这种组合将高通量和一流的安捷伦自动化液体处理技术与 AssayMAP 微量色谱技术完美配合，通过精确的流路控制实现真正的色谱分离。
 
    安捷伦生命科学事业部液相分析分部副总裁兼总经理 Fred Strohmeier 说：“我们很荣幸能将我们重要的合作伙伴 BioSystem Development 招至麾下。BioSystem Development创新且通用的微量色谱技术以及团队的应用专长将助安捷伦一臂之力，为生命科学市场带来更全面的样品制备产品。”
 
    随着生命科学发现和开发继续致力于更好地理解疾病的生物学响应，因此对于高通量、高质量的蛋白质样品制备和分析的需求日益突出。BioSystem Development 的 AssayMAP 平台基于一次性微量色谱柱，为生物过程开发、生物标记物鉴定和分析以及众多其他生命科学研究应用提供了高通量的蛋白质纯化、表征和分析解决方案。强大的 AssayMAP 技术配合安捷伦自动化液体处理能力，能够大大节省药物发现和开发的时间，提高实验室生产效率。
 
    BioSystem Development 的 CEO Scott Fulton 称：“作为业内领先的创新自动化解决方案提供商，我们很荣幸能加入安捷伦旗下。我们期望借助安捷伦的全球影响力、研发能力和丰富的产品线来扩展和增强我们的解决方案。”
 
有关 BioSystem Development 的更多信息，请访问 www.biosystemdevelopment.com。

Agilent收购Halo Genomics,下一代DNA测序市场的创新技术的供应商

 收购Halo公司及BioSystem公司 大力扩展生命科学业务

　　2011年12月1日，安捷伦科技公司对外宣布了两项收购交易，以更加深入涉足生命科学领域。两项交易的具体财务条款尚未披露。

　　其中一项交易是收购Halo Genomics公司。据了解，Halo公司位于瑞典乌普萨拉科学园，其前身为Olink Genomics公司，专注于为新一代测序平台提供目标基因富集技术，使其在过去两年发展极为迅速。虽然公司雇员不超过20人，但却拥有用于基因测序的PCR核心技术——HaloPlex技术，基于该技术的系统具有可扩展性、灵活性等特点。

　　另外一项交易则是收购BioSystem Development公司。BioSystem公司成立于2002年，总部设在美国威斯康星州麦迪逊，致力于创造、生产和推广各类生命科学工具和产品，以满足生物制药领域不断增长的重要分析需求，曾在2010年与安捷伦科技联手推出微量色谱系统。安捷伦收购BioSystem公司资产的交易预计将于今年年底完成。

　　在一份声明中，安捷伦生命科学部门的生物系统业务副总裁Gustavo Salem表示，这起收购将会增强安捷伦科技的测序产品组合，并加快公司在快速增长的下一代临床测序市场的进入速度。

　　安捷伦生命科学部门总裁Nick Roelofs则表示，生命科学业务是安捷伦科技公司收入一个很重要的增长引擎，而这两项收购将在公司的发展战略中起到重要作用。我们获得了世界一流的技术与知识，将有助于安捷伦扩大相关产品组合，为客户提供最完整的工作流程解决方案。

Agilent Technologies Grows Life Sciences Business with Strategic Acquisitions in Next-Generation Sequencing and Automated Analytical Solutions for Pharma

SANTA CLARA, Calif., Dec. 1, 2011

Agilent Technologies Inc. (NYSE: A) today announced it is expanding its life sciences business with two strategic acquisitions. Halo Genomics, a provider of innovative technology for the rapidly growing next-generation DNA sequencing market, has now joined Agilent. In addition, Agilent has signed a definitive acquisition agreement with BioSystem Development, a company that creates and manufactures solutions to meet the analytical needs of the life sciences industry.

Both companies are privately held. Financial details were not disclosed.

"Life science is the growth engine for Agilent, and these acquisitions are strategically very important," said Nick Roelofs, president of Agilent's Life Sciences Group. "We're getting world-class technology and expertise in two key areas that will help us expand our portfolio and deliver the most complete workflow solutions for our customers."

The acquisition of Halo, based in Uppsala, Sweden, is now final. The asset acquisition of BioSystem Development, headquartered in Madison, Wis., is expected to be completed by the end of the calendar year, subject to customary closing conditions.

Halo Genomics Simplifies Resequencing

Halo Genomics' technology addresses sequence-selective (or "target enrichment") sample preparation in next-generation sequencing. The company's proprietary HaloPlex technology combines the speed and specificity of polymerase chain reaction-based systems with the scalability and capture-size flexibility of solution-based hybridization formats, thus eliminating the need for library preparation. This fast and simplified target enrichment solution for next-generation sequencing helps to remove bottlenecks associated with targeted resequencing without the use of expensive, dedicated instrumentation or laborious protocols.

Halo Genomics' current HaloPlex technology is offered as a customizable product, using a Web-based design tool called Web Design Wizard. This highly intuitive tool enables users to create designs in less than 10 minutes, at no charge.

Agilent's market-leading SureSelect target enrichment platform was the first commercial in-solution target enrichment offering launched in the market. It has grown to a wide portfolio of products, from all-exon kits to custom designs and preset panels. With its high performance and flexibility, SureSelect has become the most commonly cited target enrichment tool in the market. HaloPlex technology complements SureSelect by providing a high-performance solution for small capture sizes, at a speed that specifically addresses the needs of the desktop sequencing market and clinical sequencing space.

"Halo Genomics' unique technology and talented R&D team will expand Agilent's solutions for emerging sequencing applications and accelerate our entry into the rapidly growing next-gen clinical sequencing market," said Gustavo Salem, vice president and general manager of Agilent's Biological Systems Division within the Life Sciences Group. "This acquisition further builds upon Agilent's position as a leader in genomics."

"Joining Agilent is a win-win situation for Halo employees and our valued customers," said Olle Ericsson, former CEO and founder of Halo Genomics. "With Halo's innovative technology and Agilent's market-leading products and long history of quality and service, we look forward to offering our customers an expanded portfolio of solutions to meet their needs."

For more information about Halo Genomics technology and services, visitwww.halogenomics.com.

BioSystem Development Addresses Evolving Sample-Prep Needs for Drug Development

BioSystem Development currently supplies Agilent's Automation Solutions business with AssayMAP cartridges used in conjunction with Agilent's Bravo liquid-handling platform for protein purification and characterization workflows. The Agilent Bravo automated liquid-handling platform and BioSystem Development's AssayMap technology combine high throughput and best-in-class automated liquid handling with AssayMAP microchromatography technology to enable true chromatographic separation with precision flow control.

"We are excited about bringing BioSystem Development, a valued partner, into Agilent," said Fred Strohmeier, vice president and general manager of Agilent's Liquid Phase Analysis Division within the company's Life Sciences Group. "BioSystem Development's innovative and versatile microchromatography technology, and the team's applications expertise, will help Agilent expand its capabilities as a sample-prep provider for the life sciences market."

As life science discovery and development continues to move toward a better understanding of biological responses to disease, the need for high-throughput, quality protein sample preparation and analysis becomes even more critical. BioSystem Development's AssayMAP platform, based on disposable microchromatography cartridges, enables high-throughput protein purification, characterization and analysis solutions for bioprocess development, biomarker identification and analysis, as well as a variety of other life science research applications. The enabling AssayMAP technology, combined with Agilent's automated liquid-handling capabilities, reduces drug discovery and development time and increases lab efficiency.

"As an industry leader in providing innovative automation solutions, we are very excited to join the Agilent family," said Scott Fulton, CEO of BioSystem Development. "We look forward to leveraging Agilent's global reach, research and development arm, and diversified product portfolio to expand and improve our solutions."

For more information about BioSystem Development, go towww.biosystemdevelopment.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available atwww.agilent.com.

# # #

Contact:

Eric Endicott 
+1 408 553 2005 
eric_endicott@agilent.com

Investor Contact:

Alicia Rodriguez
+1 408 345 8948
alicia_rodriguez@agilent.com